Thomas Conley, DO
Family Medicine · Sandusky, OHNPI 1811128077
Payments from drug & device makers
Across 211 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$478
- Pfizer$389
- GSK$200
- Novo Nordisk$197
- Amgen$174
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,655100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,017 |
| AstraZeneca | 28 | $478 |
| Pfizer | 24 | $389 |
| GSK | 12 | $200 |
| Novo Nordisk | 13 | $197 |
| Amgen | 10 | $174 |
| Lilly USA, LLC | 9 | $146 |
| Abbott | 7 | $145 |
| Exact Sciences | 5 | $97 |
| Boehringer Ingelheim | 5 | $84 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Novartis | 4 | $54 |
| Astellas Pharma US Inc | 3 | $53 |
| Inspire Medical Systems, Inc. | 2 | $50 |
| Dexcom, Inc. | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Bayer | 1 | $37 |
| Sanofi-aventis U.S. LLC | 1 | $35 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Johnson & Johnson | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Cranial Technologies, Inc | 1 | $18 |
| Merck | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Shield Therapeutics Inc | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Si-bone, Inc. | 1 | $14 |
How this compares
$3,667 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 153 | $138,699 |
| TrulicityDulaglutide | 100 | $118,435 |
| EliquisApixaban | 91 | $108,428 |
| JanuviaSitagliptin Phosphate | 83 | $100,160 |
| XareltoRivaroxaban | 111 | $100,061 |
| JardianceEmpagliflozin | 64 | $72,008 |
| OzempicSemaglutide | 50 | $67,321 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $32,513 |
| TradjentaLinagliptin | 15 | $19,681 |
| LinzessLinaclotide | 29 | $18,928 |
| VraylarCariprazine Hcl | 12 | $16,887 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $11,132 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $11,039 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,615 |
| MyrbetriqMirabegron | 17 | $8,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $200 | $160,446195 claims |
| Lilly USA, LLCTrulicity | $146 | $118,435100 claims |
| PfizerEliquis, Paxlovid | $389 | $115,460110 claims |
| MerckJanuvia, Janumet | $17 | $111,19994 claims |
| Johnson & JohnsonXarelto | $21 | $100,061111 claims |
| Boehringer IngelheimJardiance, Tradjenta | $84 | $91,68979 claims |
| Novo NordiskOzempic | $197 | $67,32150 claims |
| AbbVieLinzess, Vraylar | $1,017 | $35,81641 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $8,95117 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $4,947352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Sandusky
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.